Cargando…

Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria

Disease modification has become a well-established concept in several therapeutic areas; however, no widely accepted definition of disease modification exists for SLE. We reviewed established definitions of disease modification in other conditions and identified a meaningful effect on ‘disease manif...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Vollenhoven, Ronald, Askanase, Anca D, Bomback, Andrew S, Bruce, Ian N, Carroll, Angela, Dall'Era, Maria, Daniels, Mark, Levy, Roger A, Schwarting, Andreas, Quasny, Holly A, Urowitz, Murray B, Zhao, Ming-Hui, Furie, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961173/ https://www.ncbi.nlm.nih.gov/pubmed/35346982 http://dx.doi.org/10.1136/lupus-2021-000634

Ejemplares similares

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data
por: Wallace, Daniel J, et al.
Publicado: (2022)

Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2020)

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2021)

The Impact of Telemedicine on Rheumatology Care
por: Tang, Wei, et al.
Publicado: (2022)

Preliminary population-based incidence and prevalence estimates of systemic lupus erythematosus: the California Lupus Surveillance Project
por: Dall'Era, Maria C, et al.
Publicado: (2014)

A glimpse into the future of systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2022)

Association of Sweet's Syndrome and Systemic Lupus Erythematosus
por: Barton, J. L., et al.
Publicado: (2011)

Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer
por: Glass, Allison S., et al.
Publicado: (2018)

Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016)

Defining the Optimal Management Strategy for Small Renal Masses
por: Dall’Era, Marc, et al.
Publicado: (2021)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
por: Collins, C E, et al.
Publicado: (2016)

Patient-Centered Outcomes Research Institute (PCORI) multisite project to develop treatment decision aids for racial/ethnic minorities with lupus nephritis
por: Yazdany, Jinoos, et al.
Publicado: (2014)

Active Surveillance for Localized Prostate Cancer – Current Practices and Recommendations
por: Wu, Jennifer N., et al.
Publicado: (2010)

Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar(®) Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient‐Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus
por: Katz, Patricia, et al.
Publicado: (2019)

Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic/Latino Persons — California, 2007–2017
por: Gianfrancesco, Milena A., et al.
Publicado: (2021)

Active surveillance for prostate cancer
por: Dall’Era, Marc A., et al.
Publicado: (2018)

Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial
por: Askanase, Anca D, et al.
Publicado: (2020)

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
por: Dall'Era, Maria, et al.
Publicado: (2015)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Dynamics of Methylation of CpG Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort
por: Lanata, Cristina M., et al.
Publicado: (2022)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries
por: Izmirly, Peter M, et al.
Publicado: (2021)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Myocarditis in systemic lupus erythematosus diagnosed by (18)F-fluorodeoxyglucose positron emission tomography
por: Perel-Winkler, Alexandra, et al.
Publicado: (2018)

Epigenetic Aspects of Systemic Lupus Erythematosus
por: Relle, Manfred, et al.
Publicado: (2015)

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
por: Furie, Richard A, et al.
Publicado: (2021)

A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus
por: Lanata, Cristina M., et al.
Publicado: (2019)

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial
por: Wallace, Daniel J., et al.
Publicado: (2022)

Molecular pathways identified from single nucleotide polymorphisms demonstrate mechanistic differences in systemic lupus erythematosus patients of Asian and European ancestry
por: Owen, Katherine A., et al.
Publicado: (2023)

Author Correction: A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus
por: Lanata, Cristina M., et al.
Publicado: (2020)

Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies
por: Tselios, Konstantinos, et al.
Publicado: (2016)

Development validation and reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50
por: Touma, Z, et al.
Publicado: (2012)

COVID-19 and systemic lupus erythematosus: a case series
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2020)

Treatment Satisfaction in Systemic Lupus Erythematosus: Development of a Patient-Reported Outcome Measure
por: Mathias, Susan D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mib0u4pca282klecrbkcs9igdt